Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Michel Allé | M | 74 |
Université Libre de Bruxelles
| 27 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Yvan de Launoit | M | - |
Unibioscreen SA
 Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline.
Université Libre de Bruxelles
| 16 Jahre |
| Francis Darro | M | - |
Unibioscreen SA
Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline.
Université Libre de Bruxelles
| 15 Jahre |
| Ugo Falcinelli | M | - |
Université Libre de Bruxelles
| 4 Jahre |
| Qiu Zhi Xue | M | 67 |
Université Libre de Bruxelles
| 6 Jahre |
| Tanguy Cornet | M | - |
Université Libre de Bruxelles
| 5 Jahre |
| Piotr Tyranowski | M | - |
Université Libre de Bruxelles
| 4 Jahre |
| Etienne van de Kerckhove | M | 60 |
Université Libre de Bruxelles
| 6 Jahre |
| Alain van Gelderen | M | 53 |
Université Libre de Bruxelles
| 6 Jahre |
| Robert Bury | M | - |
Université Libre de Bruxelles
| 4 Jahre |
| Herjan Coelingh Bennink | M | - |
Université Libre de Bruxelles
| 8 Jahre |
| Pedro de Boeck | M | 59 |
Université Libre de Bruxelles
| 4 Jahre |
| Stéphanie Vanden Broecke | F | - |
Université Libre de Bruxelles
| 3 Jahre |
| Jean-François Hoffelt | M | 62 |
Université Libre de Bruxelles
| 1 Jahre |
| Nourredine Chinek | M | - |
Université Libre de Bruxelles
| 4 Jahre |
| Tuan Van Nguyen | M | 54 |
Université Libre de Bruxelles
| 2 Jahre |
| Bo I. Nilsson | M | - |
Unibioscreen SA
Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
| Daniel Grossmann | M | 53 |
Université Libre de Bruxelles
| 5 Jahre |
| Aminata Kaké | F | 47 |
Université Libre de Bruxelles
| 4 Jahre |
| Steven D. Weitman | M | - |
Unibioscreen SA
Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
| Frederic Halkin | M | - |
Université Libre de Bruxelles
| 1 Jahre |
| Emmanuel Lacroix | M | - |
Université Libre de Bruxelles
| 4 Jahre |
| Alain Beyens | M | 63 |
Université Libre de Bruxelles
| 4 Jahre |
| Huong Giang Thi Luong | F | 57 |
Université Libre de Bruxelles
| 2 Jahre |
| Benoît Taymans | M | - |
Université Libre de Bruxelles
| 4 Jahre |
| Muriel de Lathouwer | F | 51 |
Université Libre de Bruxelles
| 4 Jahre |
| Ayuporn Karnasuta | F | - |
Université Libre de Bruxelles
| 2 Jahre |
| Filip Kegels | M | 58 |
Université Libre de Bruxelles
| 2 Jahre |
| Nazmul Karim Chowdhury | M | 74 |
Université Libre de Bruxelles
| 3 Jahre |
| Gaudiana Giusti | F | 61 |
Université Libre de Bruxelles
| 3 Jahre |
| Gonzalo Tradacete Gallart | M | - |
Université Libre de Bruxelles
| 5 Jahre |
| Ann J. Barbier | M | 59 |
Université Libre de Bruxelles
| 3 Jahre |
| André Boulanger | M | - |
Université Libre de Bruxelles
| 4 Jahre |
| Christian Pierre B van Schoote | M | 59 |
Université Libre de Bruxelles
| 4 Jahre |
| Thomas Spitaels | M | - |
Université Libre de Bruxelles
| 4 Jahre |
| Eric van Quaquebeke | M | - |
Unibioscreen SA
Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | 9 Jahre |
| Marc Hellemans | M | 51 |
Université Libre de Bruxelles
| 4 Jahre |
| Frédéric Zoller | M | - |
Université Libre de Bruxelles
| 4 Jahre |
| Sven Arne Andréasson | M | 72 |
Unibioscreen SA
Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
| Kristel Verleyen | F | 53 |
Université Libre de Bruxelles
| 3 Jahre |
| Amelie Coens | F | - |
Université Libre de Bruxelles
| 4 Jahre |
| Axel Miller | M | 58 |
Université Libre de Bruxelles
| 5 Jahre |
| Olivier Roger J. Majérus | M | 62 |
Université Libre de Bruxelles
| 1 Jahre |
| Dimitri Dimitriou | M | - |
Unibioscreen SA
Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
| Matthias de Raeymaeker | M | 49 |
Université Libre de Bruxelles
| 2 Jahre |
| Hennie R. Hoogenboom | M | - |
Université Libre de Bruxelles
| 4 Jahre |
| Antoine Duchateau | M | 70 |
Université Libre de Bruxelles
| 1 Jahre |
| Bruno Jean Edmond Lambert | M | 65 |
Université Libre de Bruxelles
| 3 Jahre |
| Jean-Philippe Waterschoot | M | 61 |
Université Libre de Bruxelles
| 4 Jahre |
| Keith Bragman | M | - |
Unibioscreen SA
Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
| Wilfried van Langenaeker | M | - |
Université Libre de Bruxelles
| 4 Jahre |
| Didier Malherbe | M | - |
Unibioscreen SA
Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
| Christiane Verhaegen | F | - |
Unibioscreen SA
Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | 5 Jahre |
| Alain Parthoens | M | 64 |
Unibioscreen SA
Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
| Didier Georges | M | - |
Unibioscreen SA
Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
| Sandrine Evrard | F | - |
Unibioscreen SA
Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
| Mathieu Francois Pierre Pasture | M | - |
Université Libre de Bruxelles
| 1 Jahre |
| Erik M. van Mulligen | M | - |
Université Libre de Bruxelles
| 2 Jahre |
| Marc Josz | M | 66 |
Université Libre de Bruxelles
| 2 Jahre |
| Christian Leclercq | M | - |
Université Libre de Bruxelles
| 4 Jahre |
| Louis Martens | M | 62 |
Université Libre de Bruxelles
| 4 Jahre |
| Robert P. Swinnen | M | - |
Université Libre de Bruxelles
| 4 Jahre |
| Marc Wahba | M | - |
Université Libre de Bruxelles
| 4 Jahre |
| Frank van Vynckt | M | - |
Unibioscreen SA
Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
| Jos Sluys | M | 61 |
Université Libre de Bruxelles
| 4 Jahre |
| Genco Sanli | M | - |
Université Libre de Bruxelles
| 4 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Belgien | 66 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Robert Kiss
- Persönliches Netzwerk
